NASDAQ:ONCT

Oncternal Therapeutics News Headlines

$6.76
-1.50 (-18.16 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.66
Now: $6.76
$7.68
50-Day Range
$5.19
MA: $7.54
$9.39
52-Week Range
$1.49
Now: $6.76
$10.56
Volume3.15 million shs
Average Volume1.72 million shs
Market Capitalization$333.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Headlines

Oncternal Therapeutics (NASDAQ ONCT) News Headlines Today

SourceHeadline
Oncternal Therapeutics (NASDAQ:ONCT) Cut to Hold at Zacks Investment ResearchOncternal Therapeutics (NASDAQ:ONCT) Cut to Hold at Zacks Investment Research
marketbeat.com - March 20 at 3:15 AM
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual MeetingOncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
finance.yahoo.com - April 12 at 8:49 AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expected to Post Quarterly Sales of $1.11 MillionOncternal Therapeutics, Inc. (NASDAQ:ONCT) Expected to Post Quarterly Sales of $1.11 Million
americanbankingnews.com - April 12 at 3:44 AM
-$0.10 EPS Expected for Oncternal Therapeutics, Inc. (NASDAQ:ONCT) This Quarter-$0.10 EPS Expected for Oncternal Therapeutics, Inc. (NASDAQ:ONCT) This Quarter
americanbankingnews.com - April 10 at 8:24 AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Forecasted to Post Q1 2021 Earnings of ($0.11) Per ShareOncternal Therapeutics, Inc. (NASDAQ:ONCT) Forecasted to Post Q1 2021 Earnings of ($0.11) Per Share
americanbankingnews.com - April 9 at 8:00 AM
Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?
finance.yahoo.com - April 8 at 8:58 AM
Investors Purchase Large Volume of Call Options on Oncternal Therapeutics (NASDAQ:ONCT)Investors Purchase Large Volume of Call Options on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - April 7 at 11:18 PM
Why Oncternal Therapeutics Stock Is Popping TodayWhy Oncternal Therapeutics Stock Is Popping Today
nasdaq.com - April 7 at 6:47 PM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Given Average Recommendation of "Buy" by BrokeragesOncternal Therapeutics, Inc. (NASDAQ:ONCT) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 6 at 6:24 PM
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by OppenheimerOncternal Therapeutics (NASDAQ:ONCT) Now Covered by Oppenheimer
americanbankingnews.com - April 6 at 5:00 PM
Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock OptionsImplied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options
finance.yahoo.com - April 5 at 12:10 PM
Brookline Capital Management Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)Brookline Capital Management Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - March 30 at 4:24 PM
Brookline Capital Acquisition Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)Brookline Capital Acquisition Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - March 30 at 11:34 AM
Short Interest in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expands By 136.6%Short Interest in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expands By 136.6%
americanbankingnews.com - March 29 at 7:20 AM
Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call TranscriptOncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript
nasdaq.com - March 19 at 5:37 PM
Analyzing The Price Action In Oncternal Therapeutics Stock TodayAnalyzing The Price Action In Oncternal Therapeutics Stock Today
msn.com - March 17 at 3:27 PM
Were Not Very Worried About Oncternal Therapeutics (NASDAQ:ONCT) Cash Burn RateWe're Not Very Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
finance.yahoo.com - March 15 at 2:29 PM
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Raises Price Target to $9HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Raises Price Target to $9
benzinga.com - March 12 at 8:33 PM
Oncternal Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.Oncternal Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
benzinga.com - March 12 at 8:33 PM
Oncternal Therapeutics: Q4 Earnings SnapshotOncternal Therapeutics: Q4 Earnings Snapshot
finance.yahoo.com - March 11 at 8:20 PM
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue EstimatesOncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
nasdaq.com - March 11 at 8:20 PM
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial ResultsOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 11 at 8:20 PM
Heres what Wall Street expects from Oncternal Therapeuticss earnings reportHere's what Wall Street expects from Oncternal Therapeutics's earnings report
markets.businessinsider.com - March 9 at 11:58 AM
Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business UpdateOncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update
finance.yahoo.com - March 4 at 8:33 AM
Oncternal Therapeutics to Participate in March Investor ConferencesOncternal Therapeutics to Participate in March Investor Conferences
finance.yahoo.com - February 24 at 8:14 AM
Oncternal Therapeutics: Recent Success Points To A Bright FutureOncternal Therapeutics: Recent Success Points To A Bright Future
seekingalpha.com - January 30 at 9:09 PM
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of DirectorsOncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
finance.yahoo.com - January 28 at 5:49 PM
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy ProgramOncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
finance.yahoo.com - January 14 at 6:15 PM
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell TherapiesOncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
finance.yahoo.com - January 7 at 6:10 PM
Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 ConferenceOncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
finance.yahoo.com - January 5 at 9:19 AM
Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional SharesOncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - December 14 at 5:27 PM
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 MillionOncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
finance.yahoo.com - December 10 at 3:27 AM
Oncternal Therapeutics Announces $40.0 Million Bought Deal OfferingOncternal Therapeutics Announces $40.0 Million Bought Deal Offering
finance.yahoo.com - December 9 at 10:27 PM
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual MeetingOncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
finance.yahoo.com - December 7 at 8:16 AM
Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now?Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now?
finance.yahoo.com - November 30 at 8:35 PM
Why Oncternals Stock Is Trading Lower TodayWhy Oncternal's Stock Is Trading Lower Today
benzinga.com - November 18 at 8:00 PM
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Pfizer, Oncternal Therapeutics, Socket Mobile, Norwegian Cruise LineBUZZ-U.S. STOCKS ON THE MOVE-Boeing, Pfizer, Oncternal Therapeutics, Socket Mobile, Norwegian Cruise Line
nasdaq.com - November 18 at 2:59 PM
Oncternal Therapeutics shares dip 20% after raising bought deal offering to $22.5MOncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M
seekingalpha.com - November 18 at 9:56 AM
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 MillionOncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
finance.yahoo.com - November 17 at 11:33 PM
Oncternal Therapeutics Announces $20.0 Million Bought Deal OfferingOncternal Therapeutics Announces $20.0 Million Bought Deal Offering
finance.yahoo.com - November 17 at 6:33 PM
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual MeetingOncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting
finance.yahoo.com - November 11 at 12:41 PM
Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Insiders?Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Insiders?
finance.yahoo.com - November 10 at 12:11 PM
Oncternal Therapeutics to Present at Stifel Virtual Healthcare ConferenceOncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
finance.yahoo.com - November 9 at 8:39 PM
Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC FilingWeek Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing
nasdaq.com - November 8 at 12:33 PM
New data on lead drug propels Oncternal Therapeutics, up 78%New data on lead drug propels Oncternal Therapeutics, up 78%
seekingalpha.com - November 5 at 2:05 PM
Stock Alert: Oncternal Therapeutics More Than DoublesStock Alert: Oncternal Therapeutics More Than Doubles
nasdaq.com - November 5 at 2:05 PM
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business UpdateOncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 4 at 6:44 PM
Oncternal Therapeutics IncOncternal Therapeutics Inc
bloomberg.com - November 1 at 12:43 PM
Oncternal Therapeutics TK216 nabs Rare Pediatric Disease tag for bone cancerOncternal Therapeutics' TK216 nabs Rare Pediatric Disease tag for bone cancer
seekingalpha.com - October 6 at 1:23 PM
Why Oncternals Stock Is Trading Higher TodayWhy Oncternal's Stock Is Trading Higher Today
benzinga.com - October 6 at 1:23 PM
Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing SarcomaOncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma
uk.finance.yahoo.com - October 6 at 8:23 AM
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.